Equities Analysts Offer Predictions for UNCY Q1 Earnings

Unicycive Therapeutics stock sees mixed analyst forecasts for upcoming quarterly results

Apr. 10, 2026 at 10:18am

Got story updates? Submit your updates here. ›

An extreme close-up of a tangle of gears, levers, and metal components in muted industrial tones, conceptually representing the institutional financial systems that support the biotech sector.Analysts' earnings predictions offer a window into the complex financial machinery powering the biotech industry.Los Altos Today

Analysts at Brookline Capital Markets have issued their Q1 2026 earnings per share estimates for Unicycive Therapeutics, Inc. (NASDAQ:UNCY). The firm's analyst K. Raja expects the company to post earnings per share of ($0.32) for the quarter, while the current full-year consensus estimate is ($0.23) per share. Brookline Capital Markets also provided estimates for Unicycive's earnings in subsequent quarters and fiscal years.

Why it matters

Unicycive Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapies for kidney diseases. Analysts' earnings projections provide insight into Wall Street's expectations for the company's financial performance, which can impact investor sentiment and the stock price.

The details

Brookline Capital Markets analyst K. Raja expects Unicycive Therapeutics to post earnings per share of ($0.32) for the first quarter of 2026. The consensus estimate for the company's current full-year earnings is ($0.23) per share. Brookline Capital Markets also issued estimates for Unicycive's Q3 2026 earnings at ($0.39) EPS, Q4 2026 earnings at ($0.34) EPS, FY2026 earnings at ($1.39) EPS, FY2027 earnings at $5.68 EPS, FY2028 earnings at $4.35 EPS, FY2029 earnings at $5.01 EPS and FY2030 earnings at $2.93 EPS.

  • Brookline Capital Markets issued their Q1 2026 earnings per share estimates for Unicycive Therapeutics on Tuesday, April 7th.
  • Unicycive Therapeutics reported its Q1 2026 earnings on Monday, March 30th.

The players

Brookline Capital Markets

An investment banking and securities firm that provides research coverage on Unicycive Therapeutics.

K. Raja

An analyst at Brookline Capital Markets who issued the Q1 2026 earnings estimates for Unicycive Therapeutics.

Unicycive Therapeutics, Inc.

A clinical-stage biopharmaceutical company focused on developing novel therapies for kidney diseases.

Got photos? Submit your photos here. ›

What they’re saying

“Brookline Capital Markets analyst K. Raja expects that the company will post earnings per share of ($0.32) for the quarter.”

— K. Raja, Analyst

What’s next

Investors will be closely watching Unicycive Therapeutics' upcoming Q1 2026 earnings report to see how the company's actual results compare to the analyst estimates.

The takeaway

Analyst projections for Unicycive Therapeutics' earnings provide insight into Wall Street's expectations for the company's financial performance, which can influence investor sentiment and the stock price. The mixed forecasts highlight the uncertainty surrounding the company's near-term outlook as it continues to develop its novel kidney disease therapies.